News

SIR-Spheres Y-90 Resin Microspheres Are a Well-Tolerated Alternative to Standard Therapies

Posted on : 01 April 2016
SIR-Spheres Y-90 Resin Microspheres Are a Well-Tolerated Alternative to Standard Therapies for Inoperable Primary Liver Cancer, New UK NICE Medtech Innovation Briefing Says Read more

Bioabsorbable PerQseal Vivasure Large Bore Femoral Closure Device Cleared in EU

Posted on : 31 January 2016
Vivasure Medical, a company out of Galway, Ireland, landed CE Mark approval to introduce in Europe its fully absorbable percutaneous vascular closure device for use in large vessel femoral arteriotomies following transcatheter procedures. Read more

Contego Medical's Paladin Carotid Postdilation Balloon System Launched in Europe

Posted on : 31 January 2016
Contego Medical announced the European commercialisation of the Paladin carotid postdilation angioplasty balloon for patients undergoing carotid stenting procedures.  Read more

Treatment results of Sir-Spheres Y-90 regardless of age

Posted on : 25 January 2016
A new analysis of the MORE data on 606 mCRC patients treated with SIR-Spheres Y-90 resin microspheres at 11 US medical centres, published late last year in Clinical Colorectal Cancer, confirms that patient age is not a barrier to appropriate treatment with the product, Sirtex has reported.  Read more

Vascular stent useful for CV lesions in children, long-term follow-up needed

Posted on : 05 October 2015
Healio reports that Bard's balloon-expandable vascular stent was useful in children with CV lesions and allowed implantation in distal and tortuous lesions, but it was associated with early fractures, according to new data.  Read more

Essential Medical Inc. Announces Successful Additional Clinical Studies For MANTA Large Bore Vascular Closure Device

Posted on : 31 August 2015
PRNewswire reported that Essential Medical, Inc., a privately held medical device company, announced that it has successfully completed additional clinical studies using its MANTA 14F Large Bore Vascular Closure device, a revolutionary vascular closure device designed to seal both 14F and 18F large bore femoral punctures. Read more

Essential Medical, Inc. Announces CE Mark Approval for New Vascular Closure Device, X-Seal

Posted on : 31 August 2015
PRNewswire reported that Essential Medical, Inc., a privately held medical device company, announced that it has received CE mark approval for X-Seal, a new vascular closure device with superior handling and closure features.  Read more

Sirflox Study Abstract released by ASCO

Posted on : 30 May 2015
Sirtex Medical Limited is pleased to announce that the American Society for Clinical Oncology (ASCO) has published the SIRFLOX Study abstract as part of the 2015 Annual Meeting Abstracts.  Read more

SIR-Spheres y-90 Resin Microspheres Recommended in New European Society of Medical Oncology (ESMO)

Posted on : 02 April 2015
Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer (mCRC) endorse radioembolisation, specifically with Yttrium-90 resin microspheres, as a clinically proven technology to \"prolong time to liver tumour progression\" in mCRC patients who have failed to respond to available chemotherapy options. Read more

FOXFIRE and FOXFIRE Global Studies Complete Patient Enrolment

Posted on : 01 April 2015
Combined data from more than 1,000 patients being collected to assess overall survival (OS) benefit of adding first-line SIR-Spheres? Y-90 resin microspheres treatment to a current chemotherapy regimen for inoperable metastatic colorectal cancer (mCRC)  Read more

Preliminary results of SIRFLOX show study did not achieve primary endpoint

Posted on : 01 April 2015
In the first-line treatment of non-resectable metastatic colorectal cancer, the preliminary analysis of the SIRFLOX study results does not show a statistically significant improvement in overall progression-free survival ie, at any site. However, the study does show a statistically significant improvement in progression-free survival in the liver. Read more

Preliminary results of SIRFLOX show study did not achieve primary endpoint

Posted on : 01 April 2015
In the first-line treatment of non-resectable metastatic colorectal cancer, the preliminary analysis of the SIRFLOX study results does not show a statistically significant improvement in overall progression-free survival ie, at any site. However, the study does show a statistically significant improvement in progression-free survival in the liver. Read more

Sirtex Announces FOXFIRE and FOXFIRE Global Studies

Posted on : 01 April 2015
Sirtex Medical Limited has announced it completed patient enrolment in FOXFIRE and FOXFIRE Global, two large-scale multi-centre clinical trials that combine liver-directed radiation therapy with SIR-Spheres Y-90 resin microspheres to a chemotherapy regimen in over 560 inoperable metastatic colorectal cancer (mCRC) patients. Read more

Sirtex Reports Preliminary SIRFLOX Study Results

Posted on : 01 April 2015
Sirtex Medical Limited (ASX: SRX) is pleased to report the preliminary results of its SIRFLOX clinical study. Based on the preliminary analysis just completed, the primary endpoint of the SIRFLOX study was not achieved. The preliminary analysis shows that adding SIR-Spheres? Y-90 resin microspheres to a current first-line systemic chemotherapy regimen for the treatment of non-resectable metastatic colorectal cancer (mCRC) does not result in a statistically significant improvement in the overall Progression-Free Survival (PFS). Overall PFS measures progression of existing tumours and/or the development of new tumours in any organ or body site. Read more

SARAH Study

Posted on : 26 March 2015
SARAH Study completes enrollment for HCC trial, results expected in 2016 Read more

FOXFIRE UPDATE

Posted on : 26 March 2015
FOXFIRE UPDATE Recruitment to FOXFIRE has now closed. Thank you to all of the sites who contributed in recruiting patients to the trial. The final total was 364; this is a fantastic achievement and will allow the overall survival statistic to be answered. Read more

Hyaluronic Acid Injection in the Treatment of Small Joint Arthritis in the Hand

Posted on : 18 February 2015
Osteoarthritis (OA) is the most common joint disease worldwide. According to the American College of Rheumatology, approximately 70 % of people over the age of 70 have radiographic evidence of osteoarthritis, though only half develop symptoms(1). Read more

Hyaluronic Acid Injection in the Treatment of Small Joint Arthritis in the Hand

Posted on : 18 February 2015
Osteoarthritis (OA) is the most common joint disease worldwide. According to the American College of Rheumatology, approximately 70 % of people over the age of 70 have radiographic evidence of osteoarthritis, though only half develop symptoms(1). Read more

Hyaluronic Acid Injection in the Treatment of Small Joint Arthritis in the Hand

Posted on : 18 February 2015
Osteoarthritis (OA) is the most common joint disease worldwide. According to the American College of Rheumatology, approximately 70 % of people over the age of 70 have radiographic evidence of osteoarthritis, though only half develop symptoms(1).  Read more

Hyaluronic Acid Injection in the Treatment of Small Joint Arthritis in the Hand

Posted on : 18 February 2015
Osteoarthritis (OA) is the most common joint disease worldwide. According to the American College of Rheumatology, approximately 70 % of people over the age of 70 have radiographic evidence of osteoarthritis, though only half develop symptoms(1).  Read more

WhichMedicalDevice is a FREE resource created by clinicians for clinicians.

Registration is free and gives you unlimited access to all of the content and features of this website.

Find out more...

Please sign in to view this content...

I have forgotten my password
Not a Member?

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.